Essential Safety Tips for Monitoring Oral JAK Inhibitors in Skin Care

What patients should know about taking oral JAK inhibitors for skin diseases

This article summarizes a recent presentation by Victoria Garcia Albea, NP, a dermatology nurse practitioner at Lahey Clinic, during the JAK Institute Summer 2026 session. The information reflects her clinical approach and the guidance she shared at that meeting. It is not a substitute for individual medical advice. (Source: Elevate-Derm, JAK Institute Summer 2026)

Why this matters

Oral JAK inhibitors are medicines that affect parts of the immune system called Janus kinase pathways. They are taken by mouth and are among the fastest-acting systemic (whole-body) treatments used in dermatology today. Because they can work quickly, they’re an important option for some people with inflammatory skin conditions. At the same time, they carry safety notices that doctors talk about with patients. Over time, growing experience and longer-term data have helped some clinicians feel more confident prescribing these drugs for carefully chosen patients. (Source: Victoria Garcia Albea, JAK Institute session)

What safety checks are commonly done before and after starting treatment

Before starting an oral JAK inhibitor, many clinicians follow a routine set of tests and screenings to help reduce risks and catch problems early. Garcia Albea describes a typical checklist she and colleagues use:

• History review for blood clots: Your provider will ask about any history of unprovoked venous thromboembolism (VTE), which means a blood clot that happened without a clear cause. If you have a history like that, your doctor may want extra evaluation before considering a JAK inhibitor. (Source: Garcia Albea)
• History of cancer: If you have had cancer in the past, your care team may consult with an oncologist to decide whether a JAK inhibitor is appropriate for you. This is a case-by-case discussion. (Source: Garcia Albea)
• Baseline infection screening: Many clinicians test for tuberculosis (TB) using a blood test called Quantiferon Gold, and they check for hepatitis B and C. HIV testing may be done if you have risk factors or ask for it. (Source: Garcia Albea)
• Baseline bloodwork: Common tests include a complete blood count (CBC) with differential (to look at different blood cells), a comprehensive metabolic panel (to check liver and kidney function and electrolytes), and a lipid panel (cholesterol and related fats). (Source: Garcia Albea)

Follow-up monitoring

After treatment starts, follow-up blood tests are often done around 12 weeks. Early in treatment, some lab values may move up or down temporarily. Instead of stopping the medicine right away, Garcia Albea recommends watching the trend. If an abnormality continues past about 12 weeks, then clinicians may reassess and consider changes. (Source: Garcia Albea)

Managing mild lab changes

For small increases in cholesterol or other mild lab changes, lifestyle measures such as diet adjustments may be tried first. These steps can help some people bring levels down without needing to stop the medication. Your clinician will discuss options based on how big the change is and your overall health. (Source: Garcia Albea)

Known safety warnings and how they affect decisions

Oral JAK inhibitors carry official warnings about possible increased risks, including serious heart-related events, some cancers, blood clots, and death. These warnings are part of the U.S. Food and Drug Administration guidance and are an important part of the conversation between patients and clinicians. That does not mean everyone will experience these problems, but it does mean doctors carefully weigh risks and benefits for each person. (Source: U.S. Food and Drug Administration, 2021)

Professional groups have also published considerations for when to start JAK inhibitors in immune-related diseases. These resources help clinicians decide who might be a good candidate and who may need extra caution. (Source: European Alliance of Associations for Rheumatology)

Treatment goals are more than clear skin

Years ago, success in dermatology often meant the visible skin cleared up. While skin improvement is still important, Garcia Albea says treatment success now includes how patients feel. That means asking about itch, pain, sleep, daily activities, and overall quality of life. These personal symptoms often guide treatment decisions just as much as what the skin looks like. (Source: Garcia Albea)

Practical points for patients

• If you and your clinician are considering an oral JAK inhibitor, expect baseline tests and follow-up labs around 12 weeks.
• Bring up any personal or family history of blood clots or cancer so your provider can properly assess risk.
• Ask whether TB, hepatitis, or HIV testing will be part of your screening plan.
• Talk about symptoms that matter to you, like itch or sleep loss. These are part of measuring whether a treatment is working for your life, not just your skin.

Tracking changes in your skin

Keeping a simple photo log or notes about how your skin looks and feels over time can be helpful. Photos and short notes about itch, pain, or sleep can make it easier to share how you’re doing with your clinician at follow-up visits.

When to contact your doctor

If you notice new or worsening symptoms such as sudden swelling or pain in a limb (possible sign of a blood clot), unexplained weight loss, new or changing lumps, fever or signs of infection, unusual bleeding, or any fast-growing or bleeding skin lesions, contact your clinician right away. These could be signs that need prompt evaluation.

Bottom line

Oral JAK inhibitors can act quickly and are an important option for some people with inflammatory skin conditions. Because of safety considerations, careful patient selection, baseline testing, and regular follow-up are widely used. Conversations between you and your clinician about your medical history, lifestyle, and what matters most to you will guide whether this treatment is right for you. Treatment decisions should always be made together with your doctor or dermatologist.

Disclaimer

This article summarizes a clinician’s presentation at a professional meeting and is intended for general information. It is not medical advice. Discuss any treatment questions with your health care provider. For urgent or serious symptoms, seek immediate medical attention.

Sources

1. Elevate-Derm. JAK Institute Summer 2026. Accessed July 30, 2026. https://elevate-derm.com/ (Source: Elevate-Derm, JAK Institute session)
2. Garcia Albea V. Victoria Garcia Albea, NP. Beth Israel Lahey Health. Accessed July 30, 2026. https://physicians.lahey.org/details/3990/victoria-garcia-albea-dermatology-burlington (Source: Victoria Garcia Albea profile)
3. US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Published September 1, 2021. Accessed July 30, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and (Source: U.S. FDA)
4. European Alliance of Associations for Rheumatology (EULAR). Points to consider on the initiation of Janus kinase inhibitors in immune-mediated inflammatory diseases. doi:10.1136/ard-2022-222979 (Source: EULAR guidance)